Financial Data and Key Metrics Changes - Total revenues for 2025 were approximately $3.2 million, an increase from $2.3 million in 2024, primarily driven by strong seed sales from the subsidiary Castera [9][26] - Research and development expenses for 2025 were approximately $4.8 million, down from $6.5 million in the same period last year, due to reduced R&D activities at Biomica and the discontinuation of operations at Canonic [10][27] - Total operating expenses for 2025 were approximately $7.7 million, significantly decreased from $11.1 million in the same period last year, attributed to reduced activity levels in subsidiaries [11][29] - The net loss for 2025 was approximately $7.7 million, compared to $9.8 million in the same period last year, reflecting decreased operating expenses and increased financing income [32] Business Line Data and Key Metrics Changes - Castera, the subsidiary responsible for seed sales, was the primary contributor to revenue growth, with revenues recognized for seed sales in 2025 [9][26] - Biomica is focused on completing its clinical trial expected in early 2026 and securing partners for its development programs, holding approximately $4 million in cash [17][21] - Laviv Bio's activities were largely sold to ICL, with a total consideration of $15.25 million, enhancing cash flow for Evogene [14] Market Data and Key Metrics Changes - The company is undergoing a strategic shift to maximize the value of Campus AI, focusing on AI-driven discovery and optimization in pharmaceuticals and agriculture [12][19] - The collaboration with Tel Aviv University aims to develop small molecule therapeutics targeting diseases caused by metabolite accumulation, leveraging Campus AI [13] Company Strategy and Development Direction - The strategic priorities include strengthening Campus AI, expanding collaborations in small molecule drug discovery, and streamlining operational expenses [12][19] - The company plans to establish a dedicated business development arm to accelerate growth in the pharmaceutical vertical and maintain strategic collaborations in agriculture [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the new strategic direction and the potential for increased investor interest as new collaborations are announced [40] - The company expects continued reductions in operating expenses in the third and fourth quarters of 2025 [42] Other Important Information - Evogene raised $4.4 million through an at-the-market facility, enhancing its financial position and providing an operational runway of approximately 18 months [18] - The company is focusing on operational discipline and long-term value creation, with plans to present its updated corporate strategy at industry conferences [23] Q&A Session Summary Question: How much caster seed inventory do you have today, both finished and expected to be finished after the harvest? - The company has a few hundred tons of castor seed ready for sale and plans to utilize its seeds for cultivation to sell grain to partners [35][36] Question: What steps need to occur before you can announce a castor oil business? - The company is currently focused on grain cultivation and selling grain to partners, with existing crushing oil factories eager for castor grain [38] Question: The stock is still low. When will it start going up? - Management indicated that they cannot control the stock market but are finalizing a new company presentation and plan to announce new collaborations that could positively impact stock value [39][40] Question: How representative are operating expenses in Q2 2025 for going forward operations? - Management confirmed that all cost reductions are fully reflected in the numbers, with expectations for continued expense declines [42] Question: What was revenue in Q2 2025? How should we think about peak sales given recent results? - The revenue in Q2 2025 was primarily from Castera, with expectations for future sales growth as the company engages with multiple partners [43][44] Question: For Campus AI platform, what catalyst milestones should we expect in the next twelve to eighteen months? - The company anticipates announcements of new collaborations and breakthroughs in technology development as key milestones [46][49]

Financial Data and Key Metrics Changes - Corteva reported top and bottom line growth with over 200 basis points of operating EBITDA margin expansion in Q2 2025 compared to the same period last year [6] - Organic sales increased by 7% year-over-year in Q2, with operating EBITDA growth of 13% and a margin expansion of 215 basis points [17][18] - For the first half of 2025, operating EBITDA was up more than $400 million to just over $3.35 billion, with a margin of nearly 31%, reflecting a 300 basis point increase [20] Business Line Data and Key Metrics Changes - The Seed Business Unit experienced a 32% increase in price and volume gains, contributing to a significant performance in North America [18] - Crop Protection business saw an 8% increase in volume, with double-digit growth in Brazil, despite a 2% decline in pricing due to competitive dynamics [18][19] - The Seed segment achieved a $70 million benefit in net royalties, exceeding expectations for the full year [7] Market Data and Key Metrics Changes - Overall agricultural fundamentals remain mixed, with growing demand for grains and oilseeds, but moderated crop prices and margins [11] - The U.S. is expected to have a record harvest, with corn futures reflecting above-average crop condition ratings [12] - The market is seeing a shift from soybeans to corn, with expectations of increased corn acreage in Brazil and Argentina [26] Company Strategy and Development Direction - Corteva is focused on operational excellence initiatives and has raised its full-year net cost improvement target to $450 million from $400 million [7] - The company remains optimistic about growth in 2026, with a focus on investing in growth platforms and delivering meaningful royalty productivity [14] - The strategy includes enhancing product offerings and leveraging out-licensing opportunities, particularly in corn and soybeans [58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit bottom line growth and meaningful margin improvement for the year [10] - The company anticipates low to mid-single-digit pricing headwinds in the Crop Protection segment for the second half of the year [9] - Management highlighted the importance of global production keeping pace with consumption, which is critical for maintaining market stability [13] Other Important Information - Corteva is on track for $1 billion in share repurchases in 2025 and announced a nearly 6% increase in the annual dividend [29] - The company expects a full-year free cash flow of approximately $1.9 billion, with a cash conversion rate of about 50% [22] Q&A Session Summary Question: What factors are influencing the forecast for the back half of the year? - Management acknowledged the tough comparison for Crop Protection and negative pricing in Brazil, while also discussing seed acreage expectations [32][33] Question: Can you elaborate on the free cash flow guidance? - Management indicated that the increase in free cash flow guidance is driven by earnings growth and lower cash taxes due to recent legislation [38][41] Question: What are the expectations for share gains in corn and soy? - Management reported strong performance in both corn and soy, with significant market share gains attributed to product performance and licensing strategies [70] Question: How is the company navigating tariff impacts on the supply chain? - Management stated that the impact of tariffs has been minimal due to proactive strategies in improving supply chain resiliency [88][90] Question: What are the expectations for Crop Protection pricing in the back half? - Management noted that while pricing pressures exist, there are signs of stabilization and potential improvement in the Crop Protection market [82][84]

Financial Data and Key Metrics Changes - Corteva reported top and bottom line growth with over 200 basis points of operating EBITDA margin expansion in Q2 2025 compared to the same period last year [5] - Organic sales increased by 7% year-over-year for the quarter, driven by gains in both seed and crop protection [15] - Operating EBITDA for the quarter grew by 13%, with a margin expansion of 215 basis points compared to the prior year [16] Business Line Data and Key Metrics Changes - The Seed business unit experienced a 32% increase in price and volume gains, contributing significantly to the first half results [16] - Crop Protection saw an 8% increase in volume, with double-digit growth in new products and biologicals [17] - The Seed and Crop Protection units combined delivered over $400 million in productivity and cost benefits, including lower commodity costs and raw material deflation [19] Market Data and Key Metrics Changes - Overall agricultural fundamentals remain mixed, with growing demand for grains and oilseeds, but moderated crop prices and margins [10] - The U.S. is expected to see a record harvest, with corn futures reflecting above-average crop condition ratings [11] - The stocks-to-use ratio for corn is expected to remain below historical averages despite the anticipated large crop [12] Company Strategy and Development Direction - Corteva is focused on investing in growth platforms and delivering top-tier technology to enhance farmer productivity and sustainability [14] - The company raised its full-year operating EBITDA guidance to $3.8 billion, reflecting confidence in continued performance [9] - There is an emphasis on out-licensing opportunities, with a projected $4 billion market potential in corn and soybeans [55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit bottom line growth and meaningful margin improvement for the year [9] - The company anticipates low to mid-single-digit pricing headwinds in the Crop Protection segment for the second half of the year [8] - Management remains optimistic about growth in 2026, with expectations for continued strong performance in key markets [13] Other Important Information - Corteva announced a nearly 6% increase in the annual dividend, marking the fifth consecutive annual increase [27] - The company is on track for $1 billion in share repurchases in 2025, reflecting a strong balance sheet and cash flow outlook [27] Q&A Session Summary Question: What factors are influencing the forecast for the back half of the year? - Management acknowledged the tough comparisons in Crop Protection and negative pricing pressures in Brazil, while also highlighting expectations for mid-single-digit acreage increases in Latin America [30][34] Question: Can you elaborate on the free cash flow guidance? - The increase in free cash flow guidance to approximately $1.9 billion is attributed to earnings growth and lower cash taxes from recent legislation [40][41] Question: What are the expectations for share gains in corn and soy? - Management indicated strong performance in both corn and soy, with significant market share gains driven by product performance and licensing opportunities [68][70] Question: How are tariffs affecting the supply chain? - The impact of tariffs has been minimal due to proactive strategies in multisourcing and supply chain management [89] Question: What are the expectations for Crop Protection pricing? - Management expects low single-digit pricing declines in Crop Protection, particularly in Brazil, but sees signs of stabilization and potential improvement in 2026 [82][83]

Group 1 - Bayer Group announced a restructuring of its crop science division to enhance global competitiveness, including the cessation of production at the Frankfurt plant by the end of 2028 [1] - The restructuring is a response to significant overcapacity and price competition from Asian generic manufacturers, aiming to maintain production facilities in Germany while offering competitive products [1][2] - The Frankfurt plant primarily produces active ingredients and formulations for herbicides, with plans to divest some production activities and transfer remaining operations to the Dormagen and Knapsack plants [1][2] Group 2 - Bayer stated that not all of the approximately 500 employees at the Frankfurt plant will lose their jobs, as some positions will be transferred due to the planned sale of certain business segments [2] - The Dormagen plant, which employs nearly 1,200 people, will see around 200 positions affected, but it will remain Bayer's largest production base for active ingredients and crop protection products [2] - Bayer's restructuring is part of a comprehensive "five-year framework" initiated in March to address challenges in the crop science division and ensure global competitiveness [2] Group 3 - In Q1, Bayer's crop science division reported a 3.3% decline in sales to €7.58 billion, with adjusted EBITDA down 10.2% to €2.557 billion [2] - The company plans to focus on strategic innovative technologies and products, emphasizing the importance of innovation in active ingredients for crop protection [2] - Bayer aims to launch several significant products from its crop science R&D activities over the next decade [2]

Financial Data and Key Metrics Changes - Company sales declined 14% year-over-year, with pricing down 9% and volume down 1% [16][17] - First quarter EBITDA declined 25% due to lower pricing and FX headwinds [21] - Free cash flow in the first quarter was negative $596 million, significantly lower than the prior year [35] Business Line Data and Key Metrics Changes - The Plant Health business outperformed the portfolio with sales up 1% year-over-year, driven by biologicals [17] - North America experienced a sales decline of 28%, primarily due to lower volume from cautious purchases [18] - Latin America grew 17% excluding FX headwinds, with increased direct sales to cotton growers in Brazil [19] Market Data and Key Metrics Changes - A strong U.S. Dollar led to a 4% FX headwind [31] - Asia saw a sales decline of 21% excluding currency impacts, driven by prudent selling and lower prices [20] - EMEA reported 7% lower sales excluding currency impact due to lower volumes [20] Company Strategy and Development Direction - The company is focusing on reducing channel inventory and implementing a post-patent strategy for Renexapia [6][11] - A new route to market in Brazil is being established to sell directly to large corn and soybean growers, expected to provide significant growth opportunities [11][12] - The growth portfolio is positioned to deliver strong growth with new active ingredients expected to perform well in 2025 [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving financial objectives for 2025, with expectations for significant momentum in the second half of the year [38] - The company anticipates revenue growth of 7% in the second half, driven by new products and the new route to market in Brazil [29] - Management noted that the impact of tariffs is manageable and will not significantly hinder reaching 2025 goals [28] Other Important Information - The effective tax rate on adjusted earnings was 14% in the first quarter, with expectations for a full-year rate of 13% to 15% [33] - Gross debt increased to approximately $4 billion due to seasonal working capital build [34] - The company expects free cash flow of $200 million to $400 million for 2025, a decrease from the prior year [35] Q&A Session Summary Question: Price trends in the crop protection market outside of diamides - Management indicated that pricing comparisons will ease in the second half of the year, with expectations for more stability [41][42] Question: Guidance on strong growth in the second half of the year - Management expressed high confidence in revenue growth driven by new products and a healthy channel situation starting in Q3 [46][49] Question: Actions to offset tariff impacts - Management clarified that cost-saving actions were planned regardless of tariffs and that they are confident in offsetting the tariff headwinds [54][56] Question: Reducing channel inventories - Management explained that they shifted focus to promoting products directly to growers, avoiding the need for significant rebates or discounts [62] Question: Updates on the DaiMod strategy - Management confirmed that pricing is lower compared to last year, and they are confident in maintaining competitiveness with generic manufacturers [66][68] Question: Customer order patterns - Management noted that customer orders are picking up speed in Q2, with a positive outlook for demand [82][84] Question: Differences between selling directly to farmers and through the channel - Management indicated that EBIT margins are similar for both sales methods, with cash conversion linked more to regional dynamics [88][90] Question: Second half EBITDA bridge - Management explained that the pricing and FX headwinds are interconnected, with expectations for a lower impact in the second half [94][96] Question: Impact of the new route to market in Brazil - Management confirmed that the new sales organization is in place and expects positive results in Q3 [106][108]

Financial Data and Key Metrics Changes - Company sales declined 14% year-over-year, with pricing down 9% and volume down 1% [17][18] - First quarter EBITDA declined 25% due to lower pricing and FX headwinds [21] - Free cash flow in the first quarter was negative $596 million, significantly lower than the prior year [33] Business Line Data and Key Metrics Changes - The Plant Health business outperformed the portfolio with sales up 1% year-over-year, driven by biologicals [18] - North America experienced a sales decline of 28%, primarily due to lower volume from cautious purchases [19] - Latin America grew 17% excluding FX headwinds, with increased direct sales to cotton growers in Brazil [19] Market Data and Key Metrics Changes - A strong U.S. Dollar led to an FX headwind of 4% [18] - Asia reported a sales decline of 21% excluding currency impacts, driven by intentional prudent selling [20] - EMEA reported 7% lower sales excluding currency impact due to lower volumes [20] Company Strategy and Development Direction - The company is focusing on decreasing product in the channel to align with customer inventory levels and implementing a post-patent strategy for Renexapia [7][8] - A new route to market in Brazil is being established to sell directly to large corn and soybean growers, expected to provide significant growth opportunities [12] - The growth portfolio is positioned to deliver strong growth with new active ingredients expected to perform well in 2025 [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving financial objectives for 2025, with expectations for significant momentum in the second half of the year [36] - The company anticipates revenue growth of 7% in the second half, driven by new products and the new route to market in Brazil [28] - Management noted that the impact of recently announced tariffs is manageable and will not significantly hinder reaching 2025 goals [27] Other Important Information - The effective tax rate on adjusted earnings was 14% in the first quarter, in line with expectations for the full year [31] - Gross debt increased to approximately $4 billion due to seasonal working capital build [32] - The company expects free cash flow of $200 million to $400 million for 2025, a decrease from the prior year [33] Q&A Session Summary Question: Price trends in the crop protection market outside of diamides - Management indicated that pricing comparisons will ease in the second half of the year, with expectations for more stability [40][42] Question: Guidance on strong growth in the second half of the year - Management expressed high confidence in revenue growth driven by new products and a healthy channel situation starting in Q3 [46][48] Question: Actions to offset tariff impacts - Management clarified that cost-saving actions were planned regardless of tariffs and are expected to be at the higher end of projections [53][56] Question: Reducing channel inventories - Management explained that reducing channel inventories involved shifting focus to end users without significant rebates or discounts [62] Question: Updates on the DaiMod strategy - Management confirmed ongoing cost reductions and confidence in growth run rates despite the upcoming patent expirations [66] Question: Alternatives for sourcing raw materials impacted by tariffs - Management highlighted flexibility in the supply chain with multiple sources for critical raw materials to limit tariff impacts [71][74] Question: Customer order patterns - Management noted that customer orders are picking up speed in Q2, with a positive dynamic observed in Europe [82] Question: Differences between selling directly to farmers and through the channel - Management indicated that the EBIT margin is similar for both sales methods, with cash conversion linked more to regional operations [86][88] Question: Second half EBITDA bridge - Management explained that the pricing and FX headwinds are interconnected, with expectations for a lower impact in the second half [94]